Codexis, Inc. (NASDAQ:CDXS) Director Patrick Y. Yang sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, April 6th. The stock was sold at an average price of $24.71, for a total value of $494,200.00.
NASDAQ CDXS opened at $23.82 on Thursday. Codexis, Inc. has a 12 month low of $9.91 and a 12 month high of $29.56. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -68.06 and a beta of 1.17. The company’s 50 day moving average is $22.21 and its two-hundred day moving average is $19.62.
Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Thursday, February 25th. The biotechnology company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.07. The firm had revenue of $21.03 million for the quarter, compared to the consensus estimate of $20.36 million. Codexis had a negative net margin of 31.08% and a negative return on equity of 21.25%. Sell-side analysts predict that Codexis, Inc. will post -0.47 earnings per share for the current fiscal year.
Large investors have recently bought and sold shares of the business. Penserra Capital Management LLC purchased a new position in shares of Codexis in the fourth quarter valued at about $30,000. International Assets Investment Management LLC bought a new stake in Codexis during the 4th quarter valued at approximately $57,000. Nisa Investment Advisors LLC raised its stake in Codexis by 18.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,140 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 800 shares during the period. Prelude Capital Management LLC purchased a new position in Codexis in the 4th quarter worth approximately $211,000. Finally, LPL Financial LLC bought a new position in Codexis in the 4th quarter worth approximately $212,000. 91.33% of the stock is currently owned by institutional investors and hedge funds.
Codexis, Inc discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.
Further Reading: Dead Cat Bounce
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.